Summary & Overview
HCPCS Q5151: Eculizumab-aagh (epysqli) Biosimilar Injection, 2 mg
HCPCS Level II code Q5151 designates a 2 mg injection of eculizumab-aagh (epysqli), a biosimilar to the complement inhibitor eculizumab. This code captures administration of a therapeutic biologic used in conditions where complement inhibition is indicated and matters nationally as biosimilar biologics expand treatment access and influence payer coverage and hospital infusion workflows. Key payers included in the national analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn how Q5151 is used to represent dosing units for a biosimilar eculizumab product, the typical sites of service such as outpatient infusion centers and physician offices, and the clinical context for complement-inhibitor therapy. The publication provides benchmarks and payer coverage perspectives, summarizes relevant policy updates affecting biosimilar biologic billing and coding, and outlines implications for service-line operations and revenue cycle processes. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code Q5151 describes an injection of eculizumab-aagh (epmysqli), biosimilar, 2 mg. The service type is therapeutic biologic injection intended for administration of a biosimilar to eculizumab. The typical site of service for this code is outpatient infusion or injection settings, including hospital outpatient departments, physician offices, and infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS) presents to an infusion center for administration of the eculizumab biosimilar Q5151 (eculizumab-aagh, 2 mg unit). The typical patient is an adult or adolescent previously diagnosed and stabilized on complement inhibitor therapy; dosing is weight- and indication-dependent and delivered intravenously. The clinical workflow includes verification of indication and prior authorization, pre-infusion assessment (vital signs, review of vaccination status for Neisseria meningitidis, medication reconciliation), medication preparation by pharmacy (reconstitution and dosing calculation using Q5151 2 mg units), intravenous access placement, infusion administration with patient monitoring for infusion reactions, documentation of lot and unit counts, and billing using the HCPCS Level II code Q5151. Typical site of service is an outpatient infusion center, hospital outpatient department, or physician office infusion suite where biologic infusion services are provided.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies; standard billing for the service. |